Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 3/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 5/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | TOP1 | P11387 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20667486 | 0.77 | ADORA2A (0.54) | FEN1ALOX5APADORA2AADORA3ADORA1 | |
| SCHEMBL24619110 | 0.76 | ADORA2A (0.46) | FEN1ALOX5APADORA2AADORA3ADORA1 | |
| SCHEMBL29727041 | 0.76 | ADORA2A (0.46) | FEN1ALOX5APADORA2AADORA3ADORA1 | |
| SCHEMBL15269504 | 0.75 | DYRK1A (0.60) | ADORA2AMETKDM4ENPC1RAB9A | |
| SCHEMBL20658454 | 0.74 | ADORA2A (0.78) | ADORA2AADORA3ADORA1MET | |
| SCHEMBL28275870 | 0.74 | L3MBTL1 (0.66) | ADORA2AADORA3ADORA1METL3MBTL1 | |
| SCHEMBL15652298 | 0.72 | KDM4E (0.48) | ADORA2AADORA3ADORA1L3MBTL1KDM4E | |
| SCHEMBL20600782 | 0.71 | ADORA2A (0.47) | ADORA2AADORA3ADORA1L3MBTL1KDM4E | |
| SCHEMBL24619115 | 0.70 | ADORA2A (0.41) | ADORA2AADORA3ADORA1METL3MBTL1 | |
| SCHEMBL9275208 | 0.69 | SLC40A1 (0.50) | L3MBTL1KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369665-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | Ryvu Therapeutics S.A. (PL) | 2020-11-26 | — | — | US | disclosed |
| US-20200369665-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | Ryvu Therapeutics S.A. (PL) | 2020-11-26 | — | — | US | disclosed |
| EP-3645536-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | Ryvu Therapeutics S.A. (PL) | 2020-05-06 | — | — | EP | disclosed |
| CN-110809577-A | Modulators of adenosine A2A receptor | 雷沃医疗有限公司 | 2020-02-18 | — | — | CN | disclosed |
| WO-2019002606-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | SELVITA S.A. (PL) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019002606-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | SELVITA S.A. (PL) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369665-A1 | IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR | ADORA2A, ADORA1, ADORA3 | FEN1 3223/4885ALOX5AP 441/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.